Total submissions: 6
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Laboratory for Molecular Medicine, |
RCV000156228 | SCV000205944 | pathogenic | Rare genetic deafness | 2013-12-12 | criteria provided, single submitter | clinical testing | The Gln4750X variant in USH2A has not been previously reported in individuals wi th hearing loss or in large population studies. This nonsense variant leads to a premature termination codon at position 4750, which is predicted to lead to a t runcated or absent protein. In summary, this variant meets our criteria to be cl assified as pathogenic (http://pcpgm.partners.org/LMM). |
| Labcorp Genetics |
RCV002515013 | SCV003524041 | pathogenic | not provided | 2022-08-31 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln4750*) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Usher syndrome (PMID: 27460420, 30073356). ClinVar contains an entry for this variant (Variation ID: 179439). For these reasons, this variant has been classified as Pathogenic. |
| Genome- |
RCV003453191 | SCV004183087 | pathogenic | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
| Baylor Genetics | RCV003453191 | SCV004200756 | pathogenic | Retinitis pigmentosa 39 | 2023-03-30 | criteria provided, single submitter | clinical testing | |
| Fulgent Genetics, |
RCV005016474 | SCV005645687 | pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2024-02-17 | criteria provided, single submitter | clinical testing | |
| Natera, |
RCV001826849 | SCV002088233 | pathogenic | Usher syndrome type 2A | 2020-09-01 | no assertion criteria provided | clinical testing |